{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:15:57Z","timestamp":1790612157986,"version":"4.1.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To develop and validate enzyme-linked immunosorbent assay (ELISA) systems for the detection of autoantibodies against the signal recognition particle (SRP), nuclear matrix protein 2 (NXP2), and small ubiquitin-like modifier activating enzyme (SAE).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Serum samples from 288 individuals were analysed, including 183 patients with idiopathic inflammatory myopathies, 20 with other neuromuscular diseases, 35 with non-idiopathic inflammatory myopathies and other systemic autoimmune rheumatic diseases, and 50 healthy controls. ELISA systems were established using recombinant SRP, NXP2, and SAE proteins expressed in insect cells or Escherichia coli. The diagnostic performance of the ELISAs was assessed in comparison with the \u2018gold-standard\u2019 immunoprecipitation assays.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The ELISAs demonstrated high concordance with immunoprecipitation assays, with positive and negative percent agreements of 97.4% and 100% for anti-SRP, 100% and 99.6% for anti-NXP2, and 100% and 99.6% for anti-SAE antibodies, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The newly developed ELISA systems showed excellent agreement with immunoprecipitation assays, supporting their applicability for routine clinical use in detecting anti-SRP, anti-NXP2, and anti-SAE autoantibodies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/mr\/roag003","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T12:31:13Z","timestamp":1770640273000},"page":"604-609","source":"Crossref","is-referenced-by-count":1,"title":["Development of enzyme-linked immunosorbent assays for the detection of myositis-specific autoantibodies against signal recognition particle, nuclear matrix protein 2, and small ubiquitin-like modifier activating enzyme"],"prefix":"10.1093","volume":"36","author":[{"given":"Akihiro","family":"Murakami","sequence":"first","affiliation":[{"name":"Medical & Biological Laboratories Co., Ltd , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Abe","sequence":"additional","affiliation":[{"name":"Medical & Biological Laboratories Co., Ltd , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Kikuchi","sequence":"additional","affiliation":[{"name":"Medical & Biological Laboratories Co., Ltd , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Kidani","sequence":"additional","affiliation":[{"name":"Medical & Biological Laboratories Co., Ltd , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiro","family":"Nishikawa","sequence":"additional","affiliation":[{"name":"Medical & Biological Laboratories Co., Ltd , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Isayama","sequence":"additional","affiliation":[{"name":"Medical & Biological Laboratories Co., Ltd , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Matsuzawa","sequence":"additional","affiliation":[{"name":"Medical & Biological Laboratories Co., Ltd , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Sato","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine , Kanagawa,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Nakashima","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine , Kyoto ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Okiyama","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Fujimoto","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Graduate School of Medicine, Osaka University , Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichizo","family":"Nishino","sequence":"additional","affiliation":[{"name":"Department of Neuromuscular Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8352-6136","authenticated-orcid":false,"given":"Masataka","family":"Kuwana","sequence":"additional","affiliation":[{"name":"Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine , Tokyo ,","place":["Japan"]},{"name":"Scleroderma\/Myositis Centre of Excellence, Nippon Medical School Hospital , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"key":"2026070605222719100_ref1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/joim.12524","article-title":"Diagnosis and classification of idiopathic inflammatory myopathies","volume":"280","author":"Lundberg","year":"2016","journal-title":"J Intern Med"},{"key":"2026070605222719100_ref2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jbspin.2017.03.005","article-title":"Inflammatory myopathies: a new landscape","volume":"85","author":"Meyer","year":"2018","journal-title":"Joint Bone Spine"},{"key":"2026070605222719100_ref3","first-page":"403","article-title":"Performance of the 2017 EULAR\/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a scoping review","volume":"42","author":"Saygin","year":"2024","journal-title":"Clin Exp Rheumatol"},{"key":"2026070605222719100_ref4","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1474-4422(18)30254-0","article-title":"Classification and management of adult inflammatory myopathies","volume":"17","author":"Selva-O'Callaghan","year":"2018","journal-title":"Lancet Neurol"},{"key":"2026070605222719100_ref5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12016-015-8510-y","article-title":"A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy","volume":"52","author":"Satoh","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"2026070605222719100_ref6","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/25785826.2018.1531188","article-title":"Clinical significance of myositis-specific autoantibodies","volume":"41","author":"Nakashima","year":"2018","journal-title":"Immunol Med"},{"key":"2026070605222719100_ref7","doi-asserted-by":"crossref","first-page":"e85062","DOI":"10.1371\/journal.pone.0085062","article-title":"The multicenter study of a new assay for simultaneous detection of multiple anti-aminoacyl-tRNA synthetases in myositis and interstitial pneumonia","volume":"9","author":"Nakashima","year":"2014","journal-title":"PLoS One"},{"key":"2026070605222719100_ref8","doi-asserted-by":"crossref","first-page":"e0154285","DOI":"10.1371\/journal.pone.0154285","article-title":"Clinical utility of an enzyme-linked immunosorbent assay for detecting anti-melanoma differentiation-associated gene 5 autoantibodies","volume":"11","author":"Sato","year":"2016","journal-title":"PLoS One"},{"key":"2026070605222719100_ref9","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jdermsci.2016.09.013","article-title":"Enzyme-linked immunosorbent assays for detection of anti-transcriptional intermediary factor-1 gamma and anti-Mi-2 autoantibodies in dermatomyositis","volume":"84","author":"Fujimoto","year":"2016","journal-title":"J Dermatol Sci"},{"key":"2026070605222719100_ref10","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41584-020-00515-9","article-title":"Immune-mediated necrotizing myopathy: clinical features and pathogenesis","volume":"16","author":"Allenbach","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"2026070605222719100_ref11","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jaut.2017.06.007","article-title":"Autoantibodies in juvenile-onset myositis: their diagnostic value and associated clinical phenotype in a large UK cohort","volume":"84","author":"Tansley","year":"2017","journal-title":"J Autoimmun"},{"key":"2026070605222719100_ref12","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1002\/art.24547","article-title":"Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis","volume":"60","author":"Gunawardena","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2026070605222719100_ref13","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/annrheumdis-2011-200697","article-title":"Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy","volume":"71","author":"Ichimura","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2026070605222719100_ref14","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1136\/annrheumdis-2012-201736","article-title":"Autoantibodies to small ubiquitin-like modifier activating enzymes in Japanese patients with dermatomyositis: comparison with a UK Caucasian cohort","volume":"72","author":"Fujimoto","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2026070605222719100_ref15","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/s41598-017-00240-6","article-title":"Clinical characteristics of anti-SAE antibodies in Chinese patients with dermatomyositis in comparison with different patient cohorts","volume":"7","author":"Ge","year":"2017","journal-title":"Sci Rep"},{"key":"2026070605222719100_ref16","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3109\/08916934.2012.755958","article-title":"Low prevalence of anti-small ubiquitin-like modifier activating enzyme antibodies in dermatomyositis patients","volume":"46","author":"Muro","year":"2013","journal-title":"Autoimmunity."},{"key":"2026070605222719100_ref17","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1002\/art.40320","article-title":"EULAR\/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"69","author":"Lundberg","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2026070605222719100_ref18","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European league against rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2026070605222719100_ref19","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.40930","article-title":"2019 European league against rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus","volume":"71","author":"Aringer","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2026070605222719100_ref20","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/14397595.2019.1709944","article-title":"2019 diagnostic criteria for mixed connective tissue disease (MCTD): from the Japan research committee of the ministry of health, labor, and welfare for systemic autoimmune diseases","volume":"31","author":"Tanaka","year":"2021","journal-title":"Mod Rheumatol"},{"key":"2026070605222719100_ref21","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/annrheumdis-2016-210571","article-title":"2016 American College of Rheumatology\/European league against rheumatism classification criteria for primary Sj\u00f6gren's syndrome: a consensus and data-driven methodology involving three international patient cohorts","volume":"76","author":"Shiboski","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2026070605222719100_ref22","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European league against rheumatism collaborative initiative","volume":"65","author":"Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2026070605222719100_ref23","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1002\/art.1780281207","article-title":"Detection of antibodies to small nuclear ribonucleoproteins and small cytoplasmic ribonucleoproteins using unlabeled cell extracts","volume":"28","author":"Forman","year":"1985","journal-title":"Arthritis Rheum"},{"key":"2026070605222719100_ref24","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1172\/JCI116343","article-title":"Autoantibody reactive with three classes of RNA polymerases in sera from patients with systemic sclerosis","volume":"91","author":"Kuwana","year":"1993","journal-title":"J Clin Invest"},{"key":"2026070605222719100_ref25","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/mus.24970","article-title":"Signal recognition particle immunoglobulin g detected incidentally associates with autoimmune myopathy","volume":"53","author":"Apiwattanakul","year":"2016","journal-title":"Muscle Nerve"},{"key":"2026070605222719100_ref26","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/art.11484","article-title":"Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy","volume":"50","author":"Kao","year":"2004","journal-title":"Arthritis Rheum"},{"key":"2026070605222719100_ref27","first-page":"1727","article-title":"Novel autoantibodies against 7SL RNA in patients with polymyositis\/dermatomyositis","volume":"32","author":"Satoh","year":"2005","journal-title":"J Rheumatol"},{"key":"2026070605222719100_ref28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-015-0277-y","article-title":"Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients","volume":"10","author":"Suzuki","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"2026070605222719100_ref29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-020-02210-2","article-title":"International myositis assessment and clinical studies (IMACS) group myositis autoantibody scientific interest group. The promise, perceptions, and pitfalls of immunoassays for autoantibody testing in myositis","volume":"22","author":"Tansley","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2026070605222719100_ref30","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1093\/rheumatology\/keaa021","article-title":"The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity","volume":"59","author":"Tansley","year":"2020","journal-title":"Rheumatology"},{"key":"2026070605222719100_ref31","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.3390\/diagnostics14192192","article-title":"Comparison of lineblot and immunoprecipitation methods in the detection of myositis-specific and myositis-associated antibodies in patients with idiopathic inflammatory myopathies: consistency with clinical diagnoses","volume":"14","author":"Angeli","year":"2024","journal-title":"Diagnostics"},{"key":"2026070605222719100_ref32","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1007\/s10067-020-04973-0","article-title":"Performance evaluation of a commercial line blot assay system for detection of myositis-and systemic sclerosis-related autoantibodies","volume":"39","author":"Hamaguchi","year":"2020","journal-title":"Clin Rheumatol"},{"key":"2026070605222719100_ref33","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1093\/rheumatology\/keae167","article-title":"Assessing the sensitivity and specificity of myositis-specific and associated autoantibodies: a sub-study from the MyoCite cohort","volume":"63","author":"Loganathan","year":"2024","journal-title":"Rheumatology"},{"key":"2026070605222719100_ref34","doi-asserted-by":"crossref","first-page":"152858","DOI":"10.1016\/j.semarthrit.2025.152858","article-title":"Analytical performance of commercial myositis-specific autoantibody tests evaluated against immunoprecipitation assays as a reference standard: a systematic review and meta-analysis","volume":"75","author":"Gono","year":"2025","journal-title":"Semin Arthritis Rheum"},{"key":"2026070605222719100_ref35","doi-asserted-by":"crossref","first-page":"496","DOI":"10.3109\/s10165-012-0663-4","article-title":"Anti-CADM-140\/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease","volume":"23","author":"Sato","year":"2013","journal-title":"Mod Rheumatol"},{"key":"2026070605222719100_ref36","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/cen3.12302","article-title":"Enzyme-linked immunosorbent assays for diagnosis of immune-mediated necrotizing myopathy","volume":"7","author":"Ikemoto","year":"2016","journal-title":"Clin Exp Neuroimmunol"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roag003\/66840363\/roag003.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/36\/4\/604\/66840363\/roag003.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/36\/4\/604\/66840363\/roag003.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T09:23:16Z","timestamp":1783329796000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/36\/4\/604\/8471187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":36,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,2,10]]},"published-print":{"date-parts":[[2026,6,30]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roag003","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,2,10]]}}}